Paradoxical normalization in childhood epilepsy.

N Amir; V Gross-Tsur

doi:10.1111/j.1528-1157.1994.tb02555.x

Home/Archive/PubMed

PubMed · 7925152

Paradoxical normalization in childhood epilepsy.

N Amir·V Gross-Tsur

View original source ↗Export metadata ↓

Abstract

We report 5 children aged 2.5 to 9 years with refractory epilepsy who, in the wake of a change in anti-epileptic drug (AED) regimen, developed paradoxical normalization (PN). Their acute psychiatric symptoms were associated with abrupt seizure cessation and normalization of the EEG. The latency periods between first seizure and advent of psychosis ranged from 1.9 to 7.0 years. Behavioral manifestations were schizophrenialike psychosis in 1, autistic withdrawal in 3, and organic mental syndrome not otherwise specified in 1. PN has heretofore been reported only in adolescents and adults after prolonged periods of poorly controlled seizures. The hypothesized precipitating factors relate to drug-induced changes in neurotransmitter systems.

Explore related subjects

Anticonvulsants Autistic Disorder Child Child, Preschool Electroencephalography Epilepsy Female Humans Male Neurocognitive Disorders Precipitating Factors Schizophrenia Substance Withdrawal Syndrome Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

N Amir, V Gross-Tsur. Paradoxical normalization in childhood epilepsy.. https://doi.org/10.1111/j.1528-1157.1994.tb02555.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Sporadic case of spinocerebellar ataxia type 17: treatment observations for managing urinary and psychotic symptoms.

Explore the source record for details and available documents.

Anticonvulsants↗

PubMed2007

Occupational dystonia affecting truncal muscles in a bricklayer.

Explore the source record for details and available documents.

Anticonvulsants↗

PubMed2007

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗